Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/35465
Title: Magnesium sulphate to prevent perioperative atrial fibrillation in cardiac surgery: a randomized clinical trial : A protocol description of the PeriOperative Magnesium Infusion to Prevent Atrial fibrillation Evaluated (POMPAE) trial.
Austin Authors: Meerman, Manon;Buijser, Marit;van den Berg, Lettie;van den Heuvel, Anne-Marthe;Hoohenkerk, Gerard;van Driel, Vincent;Munsterman, Luuk;de Vroege, Roel;Bailey, Michael;Bellomo, Rinaldo ;Ludikhuize, Jeroen
Affiliation: Department of Intensive Care, HagaZiekenhuis, The Hague, The Netherlands.
Department of Cardiology, HagaZiekenhuis, The Hague, The Netherlands.
Department of Intensive Care, HagaZiekenhuis, The Hague, The Netherlands.
Department of Cardiothoracic Surgery, HagaZiekenhuis, The Hague, The Netherlands.
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Intensive Care
Department of Intensive Care, HagaZiekenhuis, The Hague, The Netherlands.
Department of Intensive Care, Royal Melbourne Hospital, Melbourne, Australia.
Issue Date: 15-Aug-2024
Date: 2024
Publication information: Trials 2024-08-15; 25(1)
Abstract: Postoperative atrial fibrillation (POAF) is a common and potentially serious complication post cardiac surgery. Hypomagnesaemia is common after cardiac surgery and recent evidence indicates that supplementation of magnesium may prevent POAF. We aim to investigate the effectiveness of continuous intravenous magnesium sulphate administration in the perioperative period to prevent POAF as compared to placebo. The (POMPAE) trial is a phase 2, single-center, double-blinded randomized superiority clinical study. It aims to assess the impact of perioperative continuous intravenous magnesium administration on the occurrence of cardiac surgery-related POAF. A total of 530 patients will be included. Eligible patients will be randomized in 1:1 ratio to the intervention or placebo group with stratification based on the presence of valvular surgery. The objective of the infusion is to maintain ionized magnesium levels between 1.5 and 2.0 mmol/L. The primary outcome measure is the incidence of de novo POAF within the first 7 days following surgery, with censoring at hospital discharge. This trial may generate crucial evidence for the prevention of POAF and reduce clinical adverse events in patients following cardiac surgery. The POMPAE trial was registered at ClinicalTrials.gov under the following identifier NTC05669417, https://clinicaltrials.gov/ct2/show/NCT05669417 . Registered on December 30, 2022. Version 3.3, dated 13-01-2023.
URI: https://ahro.austin.org.au/austinjspui/handle/1/35465
DOI: 10.1186/s13063-024-08368-3
ORCID: 
Journal: Trials
Start page: 540
PubMed URL: 39148128
ISSN: 1745-6215
Type: Journal Article
Subjects: Cardiac surgery
Magnesium sulphate
Postoperative atrial fibrillation
Randomized clinical trial
Atrial Fibrillation/prevention & control
Atrial Fibrillation/etiology
Atrial Fibrillation/diagnosis
Magnesium Sulfate/administration & dosage
Magnesium Sulfate/adverse effects
Cardiac Surgical Procedures/adverse effects
Postoperative Complications/prevention & control
Postoperative Complications/etiology
Perioperative Care/methods
Appears in Collections:Journal articles

Show full item record

Page view(s)

8
checked on Nov 4, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.